ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

GSK will acquire cancer drug firm Tesaro

by Ryan Cross
December 14, 2018 | APPEARED IN VOLUME 96, ISSUE 49

 

09649-buscon15-niraparib.jpg

GlaxoSmithKline will purchase Tesaro, which sells a PARP inhibitor cancer drug, for $5.1 billion. Niraparib, sold under the name Zejula, inhibits an enzyme involved in DNA repair called poly(ADP-ribose) polymerase, or PARP. Blocking PARP-mediated DNA repair in tumors that already have a gene mutation can deal the tumors a fatal blow. In the first three quarters of 2018, Tesaro posted only $166 million in niraparib sales, but GSK is counting on revenues to increase in the future.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment